DEENOVA
Deenova today publicly disclosed that its remarkable European market success in 2020 steadily expanded to Italy during 2021, with the recent Public Tender Award won by Deenova at ASST Vimercate Hospitals for multiple D1 unit-dose robots including 6 All-In-1 Stations , 40 modules of Barcode, Fridge and/or Narcotic cabinets, and the continuous utilisation of Deenova’s world-class of full service unit-dose and multi-dose medications solutions.
Giorgio Pavesi , Managing Director of Deenova in Italy stated: “It is a confirmation of our European market momentum that started in 2020, to combine new business robot and service contracts at premier hospitals in Europe with additional purchase of technologies and complex services by previous Deenova customers, clearly showing a high level of continued satisfaction with our automation solutions amongst our existing customer base, such as Vimercate Hospital .”
ASST Vimercate Hospitals are 5 state-of-the-art acute and non acute hospitals in the territory of Brianza, where architecture, technology and organisation are all aimed at placing the patient at the centre of the logistic and diagnostic-therapeutic paths. They include: Hospital of Vimercate, Hospital Presidium of Desio, Hospital of Carate Brianza, Seregno Hospital Presidium, Presidio Ospedaliera di Giussano with approximately 900 beds.
Christophe Jaffuel , Deenova Chief Commercial Officer, stated: “These 2 latest multi-year Public Tender wins (San Camillo and ASST Vimercate ) highlight Deenova main differentiating characteristics compared to other suppliers: patient care crafted for compliance, better safety and therapy compliance, and 24/7 availability.”
Since 2004, Deenova is the undisputed leading supplier of combined mechatronics (robotic and automation) solutions for closed loop medications and medical devices traceability in the healthcare industry, anytime and anywhere.
Deenova’s unique and fully integrated solutions have and will greatly contribute to ease healthcare providers’ growing pressures to: simultaneously improve patient safety, reduce therapy errors, minimise waste and controlled substance diversion, contain costs, and diminish the gap between rising patient volume/acuity and scarce medical staff.
Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%.
Please visit www.deenova.com for additional information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210711005024/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SecurityBridge Announces CEO Transition to Accelerate Global Expansion12.1.2026 15:15:00 CET | Press release
SecurityBridge, a leading provider of cybersecurity solutions for SAP, today announced the appointment of Jesper Zerlang as Chief Executive Officer, effective January 1, 2026. Zerlang transitions from his role as Chairman of the Board, a position he has held for the past 12 months, as the company enters its next phase of international expansion, backed by funds advised by BUBregal Unternehmerkapital (BU). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112824449/en/ Jesper Zerlang appointed Chief Executive Officer, SecurityBridge SecurityBridge protects SAP environments for large enterprises by reducing cyber risk across mission-critical SAP landscapes. The company is trusted by global customers to safeguard systems that power core operations, financial processes, supply chains, and digital transformation programs. “SecurityBridge is uniquely positioned at the intersection of cybersecurity and SAP – a domain I know deeply
New Clinical Study Publication Validates Respiratory Outcomes for the Onera Home-polysomnography System12.1.2026 14:30:00 CET | Press release
The results of this study provide further clinical evidence that patient-applied, patch-based PSG is a viable alternative to in-lab PSG, enabling broader access to gold-standard sleep testing. Onera Health, a leader in transforming sleep medicine, announces the recent publication of a multicenter validation study of its Onera Sleep Test System (STS) in the ERJ Open Research, a leading, fully open-access scientific journal published by the European Respiratory Society (ERS). This is the second publication from this study, and it demonstrates that the patch-based Onera STS home-polysomnography (hPSG) device accurately identifies respiratory events and distinguishes AHI severity when validated against simultaneous in-lab polysomnography and is a viable option for unattended home use. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112821647/en/ Patient sleeps with the patient-applied Onera home Polysomnography (Onera hPSG) so
Riskified Analysis Reveals 1 in 4 Refund Dollars Is Abusive; Introduces "Dynamic Returns," a New Policy Protect Feature, to Safeguard Revenue While Increasing Customer Satisfaction12.1.2026 14:00:00 CET | Press release
Riskified (NYSE: RSKD) a leader in ecommerce fraud and risk intelligence, today released a research analysis highlighting a growing customer experience dilemma: As merchants tighten controls to fight a surge in return and refund abuse, they are inadvertently creating a more restrictive and frustrating experience for their best customers. To help retailers mitigate this challenge, Riskified has introduced a new feature in its Policy Protect solution, Dynamic Returns, AI-powered return decisions that adapt in real-time based on customer eligibility. Riskified's 2024 analysis of over a million refund claims found that 1-2% of total order value measured in sales dollars was requested back as refunds, with nearly 1 in 4 dollars claimed being abusive. In response to rising abuse, many retailers are implementing restrictive tactics like flat return fees, shorter return windows, and delaying refunds, often taking 10+ days for warehouse inspection. These measures frustrate good customers, as 68
Esri’s Custom Chart Builder Adopted by the Shom (French Hydrographic and Oceanographic Office) for Nautical Chart Production12.1.2026 14:00:00 CET | Press release
Geospatial Solution for Safety-Critical Maritime Use Sets Global Benchmark for Chart Automation Esri, the global leader in location intelligence, announced today that the Shom (French Hydrographic and Oceanographic Office) has officially adopted Custom Chart Builder (CCB) for automated production of all paper nautical charts. Following extensive testing and configuration, Shom confirmed that CCB-generated charts meet the stringent safety standards required by the French Navy, marking a pivotal advancement in automating maritime cartography and reinforcing its role as a pioneer in maritime digital transformation. “This adoption demonstrates that high-quality, regulation-compliant paper charts can now be produced without manual intervention, dramatically reducing production time and cost,” said Rafael Ponce, Esri principal maritime consultant. “Shom’s endorsement validates Esri’s CCB as a trusted solution for hydrographic offices worldwide, supporting the transition to digital-first work
Cellares Expands Global Smart Factory Network With European Headquarters in the Netherlands12.1.2026 13:30:00 CET | Press release
Cellares’ new IDMO Smart Factory in Leiden, Netherlands, expands commercial-scale manufacturing capacity for European cell therapy patient populations through a standardized, automated, and highly scalable facility model Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced it has secured a site and signed a long-term lease for a new IDMO Smart Factory at Leiden Bio Science Park (LBSP) with Dura Vermeer Commercieel Vastgoed. The facility will serve as Cellares’ European headquarters and expand the company’s global manufacturing network with dedicated regional capacity. Cell therapy manufacturing is patient-specific and time-sensitive, making regional production capacity increasingly important as programs advance from clinical development toward commercial supply. The new Netherlands hub is designed to provide European drug developers with access to automated manufacturing infrastructure, while maintaining alignment to a common production stan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom